SAN DIEGO — Patients with idiopathic pulmonary fibrosis (IPF) had significant improvements in lung function and reversal of lung fibrosis measures after 12 weeks of therapy with an investigational ...

Promising results from a phase 2 trial of ENV-101, a novel hedgehog inhibitor, showed improvement in lung function and reduction of fibrosis in patients with idiopathic pulmonary fibrosis, said Paul ...

A discovery with major implications for cancer treatment has been made by a team of researchers from Rensselaer Polytechnic Institute (RPI), the University of Nebraska Medical Center (UNMC), ...

Please provide your email address to receive an email when new articles are posted on . The FDA granted an orphan drug designation to novel hedgehog pathway inhibitor taladegib, also known as ENV-101, ...

Analysis of effectiveness of FLOT perioperative chemotherapy in resectable locally advanced gastric or esophago-gastric junction cancer in a Kazakhstani population. Efficacy and safety of donafenib ...

Co announces that Infinity has regained from MedImmune, which is wholly owned by AstraZeneca (AZN), all development and worldwide commercialization rights for Infinity's Hedgehog cell-signaling ...

Epithelioma Treatment Market to reach USD 13.1 billion by 2035, driven by rising skin cancer cases and growing adoption of ...